Skip to main content
Bioton S.A. logo

Bioton S.A. — Investor Relations & Filings

Ticker · BIO ISIN · PLBIOTN00029 LEI · 259400I5R1L3OPCGII81 WAR Manufacturing
Open in API
Filings indexed 697 across all filing types
Latest filing 2018-07-13 Regulatory Filings
Country PL Poland
Listing WAR BIO

About Bioton S.A.

https://bioton.com/en/

Bioton S.A. is a biotechnology company focused on providing comprehensive solutions for diabetes care. The company's core activity is the development and production of recombinant human insulin, positioning it as a significant commercial manufacturer globally. Its operations cover the full biotechnological process, from DNA research and development to the manufacturing and marketing of finished medicinal products. The product portfolio is centered on various forms of insulin and is complemented by modern automatic injection systems designed to facilitate effective diabetes treatment for patients.

Recent filings

Filing Released Lang Actions
Podpisanie Umowy o współpracy przez Emitenta i Sequoia - Content (PL)
Regulatory Filings Classification · 95% confidence The document text is a formal announcement in Polish, referencing a previous current report ('raport bieżący nr 18/2018') and detailing a newly signed cooperation agreement ('umowa współpracy') between Bioton S.A. and Sequoia sp. z o.o. regarding production, distribution, and promotion of medical products. It outlines mutual obligations, compensation structures, penalty clauses, and termination rights. The legal basis cited is Article 17(1) of the EU Market Abuse Regulation (MAR). This type of disclosure, detailing a significant contract or transaction that could impact the company's financial standing or operations, is typically classified as a material event disclosure. In the context of the provided definitions, this is a significant business/contractual update that doesn't fit neatly into financial reports (10-K, IR), management changes (MANG), or specific financing events (CAP). Since it is a report of a material event under MAR, and it is not a standard financial report, it falls best under the general regulatory announcement category, which is RNS (Regulatory Filings), as it is a specific disclosure mandated by market rules that doesn't match a more specific category like DIRS, DIV, or M&A (TAR). The document length (10105 chars) confirms it is the full disclosure, not just an announcement of a report (RPA).
2018-07-13 Polish
Ujawnienie opóźnionej informacji – rozpoczęcie negocjacji - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a short announcement from the Management Board of Bioton S.A. (Emitent) referencing Article 17 of the MAR Regulation (EU) No 596/2014. It discloses the conclusion of negotiations and the signing of a cooperation agreement with Sequoia, which was previously delayed information. This type of disclosure, concerning material non-public information (MNPI) release under MAR, often falls under general regulatory announcements, especially when it relates to business agreements rather than specific financial results (ER/IR), capital changes (CAP/SHA), or insider trading (DIRS). Given the content is a specific, material business update disclosed under EU market abuse regulation, and it doesn't fit neatly into the other specific categories like M&A (TAR) or Financing (CAP), the most appropriate general category for mandatory regulatory disclosures that aren't standard periodic reports is Regulatory Filings (RNS). The document length is very short (1317 chars), suggesting it is an announcement rather than a full report.
2018-07-13 Polish
Złożenie zapisu na sprzedaż akcji SciGen Ltd. posiadanych przez Bioton S.A. - Content (PL)
M&A Activity Classification · 95% confidence The document text discusses a specific corporate action: the Issuer (Bioton S.A.) subscribing to a tender offer for shares in SciGen Ltd. following an announcement by Yifan International Pharmaceutical Co., Ltd. This involves a change in shareholding structure and a transaction related to securities/ownership. The text cites Article 17(1) of MAR (Market Abuse Regulation), which typically relates to the disclosure of inside information. This type of announcement, detailing a significant transaction or change in ownership interest, most closely aligns with a Major Shareholding Notification (MRQ) or potentially a general Regulatory Filing (RNS). Since it details the consequence of a tender offer response and resulting ownership change, MRQ is a strong candidate, although it is not a standard notification of crossing a threshold, but rather an update on a major transaction. Given the context of a tender offer response leading to a change in control/ownership structure, and the lack of a specific 'M&A Activity' (TAR) code for tender offer updates specifically, MRQ (Major Shareholding Notification) or RNS (Regulatory Filing) are the closest fits. Because it is a specific update on a transaction impacting ownership, MRQ is slightly more specific than the general RNS fallback. However, since the core event is the response to a takeover/tender offer, TAR (M&A Activity) is also relevant, but TAR is defined as 'merger proposals or takeover bids'. This is the *result* of a bid. Given the nature of the disclosure under MAR regarding a significant event impacting ownership, and the short length suggesting an immediate regulatory disclosure, I will classify it as a general Regulatory Filing (RNS) as it is a mandatory disclosure under EU regulation that doesn't perfectly fit the other specific transaction codes like DIV, SHA, or POS, and is not a full report.
2018-07-09 Polish
Uzyskanie zgód regulacyjnych przez Yifan International Pharmaceutical Co., Ltd. - Content (PL)
M&A Activity Classification · 95% confidence The document text is very short (938 characters) and references a prior report (raport bieżący nr 7/2018). It announces that a condition precedent related to an investment agreement has been met, obligating an investor to launch a tender offer for shares of SciGen Ltd. This type of announcement, concerning a significant corporate action like a mandatory tender offer resulting from an investment agreement, falls under major corporate events. Given the context of a mandatory tender offer resulting from a prior agreement, it is most closely related to M&A Activity (TAR). However, since it is a regulatory disclosure referencing MAR (Market Abuse Regulation) and announcing a specific corporate event outcome rather than the M&A deal itself, and given the short length suggesting an announcement rather than a full prospectus, it fits best under the general 'Regulatory Filings' (RNS) category if TAR is too specific for the *outcome* announcement, or TAR if the tender offer initiation is the core subject. Since the core event is the fulfillment of conditions leading to a mandatory takeover bid, TAR (M&A Activity) is the most appropriate specific classification over the general RNS fallback. The document is an official regulatory disclosure (MAR reference) about a significant transaction trigger.
2018-07-03 Polish
Odpowiedź na pytania Akcjonariuszy ZWZ
AGM Information Classification · 98% confidence The document is dated June 25, 2018, and explicitly references questions asked during the Annual General Meeting (Walne Zgromadzenie Akcjonariuszy) held on June 11, 2018. The content consists of formal responses from the Management Board (Prezes Zarządu) to specific shareholder inquiries raised during that meeting. This structure—a formal follow-up addressing questions posed at the AGM—is characteristic of materials related to the Annual General Meeting process. While it is a response letter, its direct context is the AGM proceedings, making 'AGM Information' (AGM-R) the most appropriate classification over a general 'Regulatory Filing' (RNS) or 'Call Transcript' (CT). The document length (2243 chars) is short, but it is a direct response document, not just an announcement of a report.
2018-06-25 Polish
Treść informacji udzielonych akcjonariuszowi - Content (PL)
AGM Information Classification · 99% confidence The document text is very short (509 characters) and explicitly states that the content attached is the 'treść informacji udzielonych akcjonariuszowi w związku z pytaniami zadanymi na Walnym Zgromadzeniu Akcjonariuszy' (content of information provided to a shareholder in connection with questions asked at the Annual General Meeting). This strongly suggests it is related to the AGM. Since it is providing the answers/information given during the AGM, it fits best under AGM Information (AGM-R), which covers presentations and materials shared during the AGM. It is not a general announcement of the meeting or voting results, but the content derived from it.
2018-06-25 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.